Type 2 diabetes mellitus and osteoarthritis

[en] OBJECTIVES: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. METHODS: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the safety of anti-OA treatments in patients with T2DM. RESULTS: T2DM has a pathogenic effect on OA through 2 major pathways involving oxidative stress and low-grade chronic inflammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk factor for OA progression and has a negative impact on arthroplasty outcomes. Evidence is mounting for safety concerns with some of the most frequently prescribed anti-OA medications, including paracetamol, non-steroidal anti-inflammatory drugs, and corticosteroid injections, while other anti-OA medications may be safely prescribed in OA patients with T2DM, such as glucosamine and intra-articular hyaluronic acid. CONCLUSIONS: Future research is needed to better understand whether diabetes control and prevention can modulate OA occurrence and progression. The selection of therapy to treat OA symptoms in patients with T2DM may require careful consideration of the evidence based to avoid untoward safety issues.

Disciplines :

General & internal medicine
Rheumatology
Orthopedics, rehabilitation & sports medicine

Author, co-author :

Veronese, Nicola

Cooper, Cyrus

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Hochberg, Marc

Branco, Jaime

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Chapurlat, Roland

Al-Daghri, Nasser

Dennison, Elaine

Herrero-Beaumont, Gabriel

More authors (8 more)

Language :

English

Title :

Type 2 diabetes mellitus and osteoarthritis

Publication date :

August 2019

Journal title :

Seminars in Arthritis and Rheumatism

ISSN :

0049-0172

eISSN :

1532-866X

Publisher :

W. B. Saunders Co., United Kingdom

Volume :

Issue :

Pages :

9-19

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 07 February 2019

Statistics

Number of views

89 (24 by ULiège)

Number of downloads

10 (10 by ULiège)

More statistics

Scopus citations^®

115

Scopus citations^®
without self-citations

107

OpenCitations

Bibliography

Guariguata, L, Whiting, DR, Hambleton, I, Beagley, J, Linnenkamp, U, Shaw, JE, Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:2 (2014), 137–149, 10.1016/j.diabres.2013.11.002.
Vos, T, Flaxman, AD, Naghavi, M, Lozano, R, Michaud, C, Ezzati, M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2163–2196, 10.1016/s0140-6736(12)61729-2.
Visser, AW, de Mutsert, R, le Cessie, S, den Heijer, M, Rosendaal, FR, Kloppenburg, M, et al. The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study. Ann Rheum Dis 74:10 (2015), 1842–1847, 10.1136/annrheumdis-2013-205012.
Teodoro, JS, Varela, AT, Rolo, AP, Palmeira, CM, High-fat and obesogenic diets: current and future strategies to fight obesity and diabetes. Genes Nutr, 9(4), 2014, 406, 10.1007/s12263-014-0406-6.
Scheen, AJ, Van Gaal, LF, Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2:11 (2014), 911–922, 10.1016/S2213-8587(14)70004-X.
CDC. Centers for disease control and prevention: national diabetes statistics report. 2017, GA Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta.
Lawrence, RC, Felson, DT, Helmick, CG, Arnold, LM, Choi, H, Deyo, RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58:1 (2008), 26–35, 10.1002/art.23176.
Defronzo, RA, Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:4 (2009), 773–795, 10.2337/db09-9028.
Stumvoll, M, Goldstein, BJ, van Haeften, TW, Type 2 diabetes: pathogenesis and treatment. Lancet 371:9631 (2008), 2153–2156, 10.1016/S0140-6736(08)60932-0.
King, KB, Rosenthal, AK, The adverse effects of diabetes on osteoarthritis: update on clinical evidence and molecular mechanisms. Osteoarthr Cartil 23:6 (2015), 841–850, 10.1016/j.joca.2015.03.031.
CDC. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation – United States, 2010-2012. Morb Mortal Wkly Rep 62:44 (2013), 869–873.
Bijlsma, JW, Berenbaum, F, Lafeber, FP, Osteoarthritis: an update with relevance for clinical practice. Lancet 377:9783 (2011), 2115–2126, 10.1016/S0140-6736(11)60243-2.
Yusuf, E, Nelissen, RG, Ioan-Facsinay, A, Stojanovic-Susulic, V, DeGroot, J, van Osch, G, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis 69:4 (2010), 761–765, 10.1136/ard.2008.106930.
Louati, K, Vidal, C, Berenbaum, F, Sellam, J, Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open, 1(1), 2015, e000077, 10.1136/rmdopen-2015-000077.
Alberti, KG, Zimmet, P, Shaw, J, Group IDFETFC. The metabolic syndrome–a new worldwide definition. Lancet 366:9491 (2005), 1059–1062, 10.1016/S0140-6736(05)67402-8.
Puenpatom, RA, Victor, TW, Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med 121:6 (2009), 9–20, 10.3810/pgm.2009.11.2073.
Zhuo, Q, Yang, W, Chen, J, Wang, Y, Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol 8:12 (2012), 729–737, 10.1038/nrrheum.2012.135.
Alberti, KG, Eckel, RH, Grundy, SM, Zimmet, PZ, Cleeman, JI, Donato, KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:16 (2009), 1640–1645, 10.1161/CIRCULATIONAHA.109.192644.
Yasuda, E, Nakamura, R, Matsugi, R, Goto, S, Ikenaga, Y, Kuroda, K, et al. Association between the severity of symptomatic knee osteoarthritis and cumulative metabolic factors. Aging Clin Exp Res 30:5 (2018), 481–488, 10.1007/s40520-017-0808-6.
Roberts, E, Delgado Nunes, V, Buckner, S, Latchem, S, Constanti, M, Miller, P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 75:3 (2016), 552–559, 10.1136/annrheumdis-2014-206914.
Lipworth, L, Abdel-Kader, K, Morse, J, Stewart, TG, Kabagambe, EK, Parr, SK, et al. High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study. BMC Nephrol, 17(1), 2016, 189, 10.1186/s12882-016-0411-7.
Heyman, SN, Khamaisi, M, Rosen, S, Rosenberger, C, Abassi, Z, Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of nsaids and iodinated contrast media. Diabetes Care 40:4 (2017), e40–ee1, 10.2337/dc16-2200.
Bhala, N, Emberson, J, Merhi, A, Abramson, S, Arber, N, Baron, JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:9894 (2013), 769–779, 10.1016/s0140-6736(13)60900-9.
Nielen, JT, Emans, PJ, Dagnelie, PC, Boonen, A, Lalmohamed, A, de Boer, A, et al. Severity of diabetes mellitus and total hip or knee replacement: a population-based case-control study. Medicine, 95(20), 2016, e3739, 10.1097/MD.0000000000003739.
Dahaghin, S, Bierma-Zeinstra, SM, Koes, BW, Hazes, JM, Pols, HA, Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam study. Ann Rheum Dis 66:7 (2007), 916–920, 10.1136/ard.2005.045724.
Magnusson, K, Hagen, KB, Osteras, N, Nordsletten, L, Natvig, B, Haugen, IK, Diabetes is associated with increased hand pain in erosive hand osteoarthritis: data from a population-based study. Arthritis Care Res 67:2 (2015), 187–195, 10.1002/acr.22460.
Frey, N, Hugle, T, Jick, SS, Meier, CR, Spoendlin, J, Type II diabetes mellitus and incident osteoarthritis of the hand: a population-based case-control analysis. Osteoarthr Cartil 24:9 (2016), 1535–1540, 10.1016/j.joca.2016.04.005.
Eymard, F, Parsons, C, Edwards, MH, Petit-Dop, F, Reginster, JY, Bruyere, O, et al. Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthr Cartil 23:6 (2015), 851–859, 10.1016/j.joca.2015.01.013.
Schett, G, Kleyer, A, Perricone, C, Sahinbegovic, E, Iagnocco, A, Zwerina, J, et al. Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study. Diabetes Care 36:2 (2013), 403–409, 10.2337/dc12-0924.
Shirinsky, IV, Shirinsky, VS, Effects of medication-treated diabetes on incidence and progression of knee osteoarthritis: a longitudinal analysis of the osteoarthritis initiative data. Rheumatol Int 37:6 (2017), 983–991, 10.1007/s00296-017-3676-7.
Barnett, LA, Jordan, KP, Edwards, JJ, van der Windt, DA, Does metformin protect against osteoarthritis? An electronic health record cohort study. Prim Health Care Res Dev 18:6 (2017), 623–628, 10.1017/S1463423617000287.
Lu, CH, Chung, CH, Lee, CH, Hsieh, CH, Hung, YJ, Lin, FH, et al. Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan. PLoS One, 13(1), 2018, e0191242, 10.1371/journal.pone.0191242.
Scheen, AJ, Esser, N, Paquot, N, Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab 41:3 (2015), 183–194, 10.1016/j.diabet.2015.02.003.
Nielen, JT, de Vries, F, Dagnelie, PC, van den Bemt, BJ, Emans, PJ, Lalmohamed, A, et al. Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control study. Br J Clin Pharmacol 81:2 (2016), 370–378, 10.1111/bcp.12786.
Courties, A, Sellam, J, Osteoarthritis and type 2 diabetes mellitus: what are the links?. Diabetes Res Clin Pract 122 (2016), 198–206, 10.1016/j.diabres.2016.10.021.
Courties, A, Gualillo, O, Berenbaum, F, Sellam, J, Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthr Cartil 23:11 (2015), 1955–1965, 10.1016/j.joca.2015.05.016.
Wang, Y, Wluka, AE, Hodge, AM, English, DR, Giles, GG, O'Sullivan, R, et al. Effect of fatty acids on bone marrow lesions and knee cartilage in healthy, middle-aged subjects without clinical knee osteoarthritis. Osteoarthr Cartil 16:5 (2008), 579–583, 10.1016/j.joca.2007.09.007.
Askari, A, Ehrampoush, E, Homayounfar, R, Bahramali, E, Farjam, M, Serum insulin in pathogenesis and treatment of osteoarthritis. Med Hypotheses 99 (2017), 45–46, 10.1016/j.mehy.2016.12.010.
Al-Jarallah, K, Shehab, D, Abdella, N, Al Mohamedy, H, Abraham, M, Knee osteoarthritis in type 2 diabetes mellitus: does insulin therapy retard osteophyte formation?. Med Princ Pract 25:1 (2016), 12–17, 10.1159/000441418.
Rosa, SC, Rufino, AT, Judas, F, Tenreiro, C, Lopes, MC, Mendes, AF, Expression and function of the insulin receptor in normal and osteoarthritic human chondrocytes: modulation of anabolic gene expression, glucose transport and GLUT-1 content by insulin. Osteoarthr Cartil 19:6 (2011), 719–727, 10.1016/j.joca.2011.02.004.
Ribeiro, M, Lopez de Figueroa, P, Blanco, FJ, Mendes, AF, Carames, B, Insulin decreases autophagy and leads to cartilage degradation. Osteoarthr Cartil 24:4 (2016), 731–739, 10.1016/j.joca.2015.10.017.
Gregor, MF, Hotamisligil, GS, Inflammatory mechanisms in obesity. Annu Rev Immunol 29 (2011), 415–445, 10.1146/annurev-immunol-031210-101322.
Griffin, TM, Huffman, KM, Editorial: insulin resistance: releasing the brakes on synovial inflammation and osteoarthritis?. Arthritis Rheumatol 68:6 (2016), 1330–1333, 10.1002/art.39586.
Hamada, D, Maynard, R, Schott, E, Drinkwater, CJ, Ketz, JP, Kates, SL, et al. Suppressive effects of insulin on tumor necrosis factor-dependent early osteoarthritic changes associated with obesity and type 2 diabetes mellitus. Arthritis Rheumatol 68:6 (2016), 1392–1402, 10.1002/art.39561.
Courties, A, Sellam, J, Berenbaum, F, Metabolic syndrome-associated osteoarthritis. Curr Opin Rheumatol 29:2 (2017), 214–222, 10.1097/BOR.0000000000000373.
Mobasheri, A, Neama, G, Bell, S, Richardson, S, Carter, SD, Human articular chondrocytes express three facilitative glucose transporter isoforms: GLUT1, GLUT3 and GLUT9. Cell Biol Int 26:3 (2002), 297–300, 10.1006/cbir.2001.0850.
Rosa, SC, Goncalves, J, Judas, F, Mobasheri, A, Lopes, C, Mendes, AF, Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in chondrocytes from osteoarthritic versus normal human cartilage. Arthritis Res Ther, 11(3), 2009, R80, 10.1186/ar2713.
Eaton, CB, Sayeed, M, Ameernaz, S, Roberts, MB, Maynard, JD, Driban, JB, et al. Sex differences in the association of skin advanced glycation endproducts with knee osteoarthritis progression. Arthritis Res Ther, 19(1), 2017, 36, 10.1186/s13075-017-1226-z.
Vos, PA, Welsing, PM, deGroot, J, Huisman, AM, Oostveen, JC, Reijman, M, et al. Skin pentosidine in very early hip/knee osteoarthritis (CHECK) is not a strong independent predictor of radiographic progression over 5 years follow-up. Osteoarthr Cartil 21:6 (2013), 823–830, 10.1016/j.joca.2013.03.006.
Chen, YJ, Sheu, ML, Tsai, KS, Yang, RS, Liu, SH, Advanced glycation end products induce peroxisome proliferator-activated receptor gamma down-regulation-related inflammatory signals in human chondrocytes via toll-like receptor-4 and receptor for advanced glycation end products. PLoS One, 8(6), 2013, e66611, 10.1371/journal.pone.0066611.
Tsai, CH, Chiang, YC, Chen, HT, Huang, PH, Hsu, HC, Tang, CH, High glucose induces vascular endothelial growth factor production in human synovial fibroblasts through reactive oxygen species generation. Biochim Biophys Acta 1830:3 (2013), 2649–2658, 10.1016/j.bbagen.2012.12.017.
Ribeiro, M, Lopez de Figueroa, P, Nogueira-Recalde, U, Centeno, A, Mendes, AF, Blanco, FJ, et al. Diabetes-accelerated experimental osteoarthritis is prevented by autophagy activation. Osteoarthr Cartil 24:12 (2016), 2116–2125, 10.1016/j.joca.2016.06.019.
Davies-Tuck, ML, Wang, Y, Wluka, AE, Berry, PA, Giles, GG, English, DR, et al. Increased fasting serum glucose concentration is associated with adverse knee structural changes in adults with no knee symptoms and diabetes. Maturitas 72:4 (2012), 373–378, 10.1016/j.maturitas.2012.05.013.
Wen, CY, Chen, Y, Tang, HL, Yan, CH, Lu, WW, Chiu, KY, Bone loss at subchondral plate in knee osteoarthritis patients with hypertension and type 2 diabetes mellitus. Osteoarthr Cartil 21:11 (2013), 1716–1723, 10.1016/j.joca.2013.06.027.
Franke, S, Ruster, C, Pester, J, Hofmann, G, Oelzner, P, Wolf, G, Advanced glycation end products affect growth and function of osteoblasts. Clin Exp Rheumatol 29:4 (2011), 650–660.
Charnley, J, Periarthritis of the shoulder. Postgrad Med J, 35(405), 1959, 384.
Kischer, CW, Speer, DP, Microvascular changes in Dupuytren's contracture. J Hand Surg 9:1 (1984), 58–62.
Schramm, JC, Dinh, T, Veves, A, Microvascular changes in the diabetic foot. Int J Low Extrem Wounds 5:3 (2006), 149–159.
Johnson, EO, Soultanis, K, Soucacos, PN, Vascular anatomy and microcirculation of skeletal zones vulnerable to osteonecrosis: vascularization of the femoral head. Orthop Clin 35:3 (2004), 285–291.
Findlay, DM, Vascular pathology and osteoarthritis. Rheumatology 46:12 (2007), 1763–1768, 10.1093/rheumatology/kem191.
Kushner, RF, Sorensen, KW, Lifestyle medicine: the future of chronic disease management. Curr Opin Endocrinol Diabetes Obes 20:5 (2013), 389–395, 10.1097/01.med.0000433056.76699.5d.
Bruyere, O, Cooper, C, Pelletier, JP, Branco, J, Brandi, ML, Guillemin, F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 44:3 (2014), 253–263, 10.1016/j.semarthrit.2014.05.014.
ADA. American Diabetes Association. 4. Lifestyle management: standards of medical care in diabetes 2018. Diabetes Care 41:Suppl. 1 (2018), S38–S50, 10.2337/dc18-S004.
Sallis, RE, Matuszak, JM, Baggish, AL, Franklin, BA, Chodzko-Zajko, W, Fletcher, BJ, et al. Call to action on making physical activity assessment and prescription a medical standard of care. Curr Sports Med Rep 15:3 (2016), 207–214, 10.1249/JSR.0000000000000249.
Hemmingsen, B, Gimenez-Perez, G, Mauricio, D, Roque, IFM, Metzendorf, MI, Richter, B, Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev, 12, 2017, CD003054, 10.1002/14651858.CD003054.pub4.
Kriska, A, Can a physically active lifestyle prevent type 2 diabetes?. Exerc Sport Sci Rev 31:3 (2003), 132–137.
Pan, XR, Li, GW, Hu, YH, Wang, JX, Yang, WY, An, ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 20:4 (1997), 537–544.
Tuomilehto, J, Lindstrom, J, Eriksson, JG, Valle, TT, Hamalainen, H, Ilanne-Parikka, P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:18 (2001), 1343–1350, 10.1056/NEJM200105033441801.
Knowler, WC, Barrett-Connor, E, Fowler, SE, Hamman, RF, Lachin, JM, Walker, EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:6 (2002), 393–403, 10.1056/NEJMoa012512.
Diabetes Prevention Program Research G Knowler, WC, Fowler, SE, Hamman, RF, Christophi, CA, Hoffman, HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 374:9702 (2009), 1677–1686, 10.1016/S0140-6736(09)61457-4.
Carnethon, MR, Craft, LL, Autonomic regulation of the association between exercise and diabetes. Exerc Sport Sci Rev 36:1 (2008), 12–18, 10.1097/jes.0b013e31815e3dc5.
Dela, F, Prats, C, Helge, JW, Exercise interventions to prevent and manage type 2 diabetes: physiological mechanisms. Med Sport Sci 60 (2014), 36–47, 10.1159/000357334.
Lumb, A, Diabetes and exercise. Clin Med 14:6 (2014), 673–676, 10.7861/clinmedicine.14-6-673.
Li, G, Zhang, P, Wang, J, An, Y, Gong, Q, Gregg, EW, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing diabetes prevention study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2:6 (2014), 474–480, 10.1016/S2213-8587(14)70057-9.
Towheed, TE, Maxwell, L, Judd, MG, Catton, M, Hochberg, MC, Wells, G, Acetaminophen for osteoarthritis. Cochrane Database Syst Rev(1), 2006, CD004257, 10.1002/14651858.CD004257.pub2.
Zhang, W, Nuki, G, Moskowitz, RW, Abramson, S, Altman, RD, Arden, NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18:4 (2010), 476–499, 10.1016/j.joca.2010.01.013.
Gulmez, SE, Larrey, D, Pageaux, GP, Bernuau, J, Bissoli, F, Horsmans, Y, et al. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study. Br J Clin Pharmacol 80:3 (2015), 599–606, 10.1111/bcp.12635.
Craig, DG, Bates, CM, Davidson, JS, Martin, KG, Hayes, PC, Simpson, KJ, Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol 73:2 (2012), 285–294, 10.1111/j.1365-2125.2011.04067.x.
Machado, GC, Maher, CG, Ferreira, PH, Pinheiro, MB, Lin, CW, Day, RO, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ, 350, 2015, h1225, 10.1136/bmj.h1225.
Williams, KH, Shackel, NA, Gorrell, MD, McLennan, SV, Twigg, SM, Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev 34:1 (2013), 84–129, 10.1210/er.2012-1009.
Dai, W, Ye, L, Liu, A, Wen, SW, Deng, J, Wu, X, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine, 96(39), 2017, e8179, 10.1097/md.0000000000008179.
Portillo-Sanchez, P, Bril, F, Maximos, M, Lomonaco, R, Biernacki, D, Orsak, B, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 100:6 (2015), 2231–2238, 10.1210/jc.2015-1966.
Massart, J, Begriche, K, Moreau, C, Fromenty, B, Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res 3:Suppl 1 (2017), 212–232, 10.18053/jctres.03.2017S1.006.
Michaut, A, Moreau, C, Robin, MA, Fromenty, B, Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int 34:7 (2014), e171–e179, 10.1111/liv.12514.
Caparrotta, TM, Antoine, DJ, Dear, JW, Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature. Eur J Clin Pharmacol 74:2 (2018), 147–160, 10.1007/s00228-017-2356-6.
Ajith, TA, Role of mitochondria and mitochondria-targeted agents in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 45:5 (2018), 413–421, 10.1111/1440-1681.12886.
Kon, K, Ikejima, K, Okumura, K, Arai, K, Aoyama, T, Watanabe, S, Diabetic KK-A(y) mice are highly susceptible to oxidative hepatocellular damage induced by acetaminophen. Am J Physiol Gastrointest Liver Physiol 299:2 (2010), G329–G337, 10.1152/ajpgi.00361.2009.
Kim, YH, Hwang, JH, Kim, KS, Noh, JR, Choi, DH, Kim, DK, et al. Metformin ameliorates acetaminophen hepatotoxicity via Gadd45beta-dependent regulation of JNK signaling in mice. J Hepatol 63:1 (2015), 75–82, 10.1016/j.jhep.2015.02.008.
Du, K, Ramachandran, A, Weemhoff, JL, Chavan, H, Xie, Y, Krishnamurthy, P, et al. Editor's highlight: metformin protects against acetaminophen hepatotoxicity by attenuation of mitochondrial oxidant stress and dysfunction. Toxicol Sci 154:2 (2016), 214–226, 10.1093/toxsci/kfw158.
Hayward, KL, Powell, EE, Irvine, KM, Martin, JH, Can paracetamol (acetaminophen) be administered to patients with liver impairment?. Br J Clin Pharmacol 81:2 (2016), 210–222, 10.1111/bcp.12802.
Kamali, F, Thomas, SH, Ferner, RE, Paracetamol elimination in patients with non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 35:1 (1993), 58–61.
Nasri, H, Rafieian-Kopaei, M, Diabetes mellitus and renal failure: prevention and management. J Res Med Sci: Off J Isfahan Univ Med Sci 20:11 (2015), 1112–1120, 10.4103/1735-1995.172845.
Pratt, N, Roughead, EE, Ryan, P, Gilbert, AL, Differential impact of NSAIDs on rate of adverse events that require hospitalization in high-risk and general veteran populations: a retrospective cohort study. Drugs Aging 27:1 (2010), 63–71, 10.2165/11531250-000000000-00000.
Roughead, EE, Ramsay, E, Pratt, N, Gilbert, AL, NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. Drug Saf 31:11 (2008), 997–1003.
Huerta, C, Castellsague, J, Varas-Lorenzo, C, Garcia Rodriguez, LA, Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 45:3 (2005), 531–539, 10.1053/j.ajkd.2004.12.005.
Fournier, JP, Sommet, A, Durrieu, G, Poutrain, JC, Lapeyre-Mestre, M, Montastruc, JL, et al. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database. Fundam Clin Pharmacol 28:2 (2014), 230–235, 10.1111/fcp.12014.
Dreischulte, T, Morales, DR, Bell, S, Guthrie, B, Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int 88:2 (2015), 396–403, 10.1038/ki.2015.101.
Lapi, F, Azoulay, L, Yin, H, Nessim, SJ, Suissa, S, Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ, 346, 2013, e8525, 10.1136/bmj.e8525.
Wong, HK, Ong, KL, Cheung, CL, Cheung, BM, Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010. Ann Epidemiol 24:7 (2014), 516–521, 10.1016/j.annepidem.2014.05.001.
Scheen, AJ, Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75:1 (2015), 33–59, 10.1007/s40265-014-0337-y.
Scheen, AJ, SGLT2 inhibitors: benefit/risk balance. Curr Diab Rep, 16(10), 2016, 92, 10.1007/s11892-016-0789-4.
Szalat, A, Perlman, A, Muszkat, M, Khamaisi, M, Abassi, Z, Heyman, SN, Can SGLT2 inhibitors cause acute renal failure? plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf 41:3 (2018), 239–252, 10.1007/s40264-017-0602-6.
Thomas, MC, Type 2 diabetes and heart failure: challenges and solutions. Curr Cardiol Rev 12:3 (2016), 249–255, 10.2174/1573403X12666160606120254.
Amer, M, Bead, VR, Bathon, J, Blumenthal, RS, Edwards, DN, Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev 18:4 (2010), 204–212, 10.1097/CRD.0b013e3181ce1521.
Maillard, M, Burnier, M, Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 5:1 (2006), 83–94, 10.1517/14740338.5.1.83.
Gunter, BR, Butler, KA, Wallace, RL, Smith, SM, Harirforoosh, S, Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther 42:1 (2017), 27–38, 10.1111/jcpt.12484.
Nissen, SE, Yeomans, ND, Solomon, DH, Luscher, TF, Libby, P, Husni, ME, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 375:26 (2016), 2519–2529, 10.1056/NEJMoa1611593.
Solomon, DH, Husni, ME, Wolski, KE, Wisniewski, LM, Borer, JS, Graham, DY, et al. Differences in safety of nonsteroidal antiinflammatory drugs in patients with osteoarthritis and patients with rheumatoid arthritis: a randomized clinical trial. Arthritis Rheumatol 70:4 (2018), 537–546, 10.1002/art.40400.
Sowers, JR, White, WB, Pitt, B, Whelton, A, Simon, LS, Winer, N, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 165:2 (2005), 161–168, 10.1001/archinte.165.2.161.
Schmidt, M, Sorensen, HT, Pedersen, L, Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ, 362, 2018, k3426, 10.1136/bmj.k3426.
Mazhar, F, Haider, N, Sultana, J, Akram, S, Ahmed, Y, Prospective study of NSAIDs prescribing in Saudi Arabia: cardiovascular and gastrointestinal risk in patients with diabetes mellitus. Int J Clin Pharmacol Ther 56:2 (2018), 64–71, 10.5414/cp203071.
Barthel, HR, Axford-Gatley, RA, Topical nonsteroidal anti-inflammatory drugs for osteoarthritis. Postgrad Med 122:6 (2010), 98–106, 10.3810/pgm.2010.11.2227.
Rannou, F, Pelletier, JP, Martel-Pelletier, J, Efficacy and safety of topical NSAIDs in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 45:4 Suppl (2016), S18–S21, 10.1016/j.semarthrit.2015.11.007.
Peniston, JH, Gold, MS, Wieman, MS, Alwine, LK, Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. Clin Interv Aging 7 (2012), 517–523, 10.2147/CIA.S35416.
Baraf, HS, Gold, MS, Petruschke, RA, Wieman, MS, Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. Am J Geriatr Pharmacother 10:1 (2012), 47–60, 10.1016/j.amjopharm.2011.12.002.
Reginster, JY, Deroisy, R, Rovati, LC, Lee, RL, Lejeune, E, Bruyere, O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357:9252 (2001), 251–256, 10.1016/S0140-6736(00)03610-2.
Pavelka, K, Gatterova, J, Olejarova, M, Machacek, S, Giacovelli, G, Rovati, LC, Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162:18 (2002), 2113–2123.
Zegels, B, Crozes, P, Uebelhart, D, Bruyere, O, Reginster, JY, Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil 21:1 (2013), 22–27, 10.1016/j.joca.2012.09.017.
Kahan, A, Uebelhart, D, De Vathaire, F, Delmas, PD, Reginster, JY, Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 60:2 (2009), 524–533, 10.1002/art.24255.
Altman, RD, Abramson, S, Bruyere, O, Clegg, D, Herrero-Beaumont, G, Maheu, E, et al. Commentary: osteoarthritis of the knee and glucosamine. Osteoarthr Cartil 14:10 (2006), 963–966, 10.1016/j.joca.2006.06.010.
Maheu, E, Cadet, C, Marty, M, Moyse, D, Kerloch, I, Coste, P, et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis 73:2 (2014), 376–384, 10.1136/annrheumdis-2012-202485.
Reginster, JY, The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 56:7 (2007), 2105–2110, 10.1002/art.22852.
Reginster, JY, Dudler, J, Blicharski, T, Pavelka, K, Pharmaceutical-grade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis 76:9 (2017), 1537–1543, 10.1136/annrheumdis-2016-210860.
Pavelka, K, Bruyere, O, Cooper, C, Kanis, JA, Leeb, BF, Maheu, E, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging 33:2 (2016), 75–85, 10.1007/s40266-016-0347-4.
Christiansen, BA, Bhatti, S, Goudarzi, R, Emami, S, Management of osteoarthritis with avocado/soybean unsaponifiables. Cartilage 6:1 (2015), 30–44, 10.1177/1947603514554992.
Towheed, TE, Maxwell, L, Anastassiades, TP, Shea, B, Houpt, J, Robinson, V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev(2), 2009, CD002946, 10.1002/14651858.CD002946.pub2.
Wandel, S, Juni, P, Tendal, B, Nuesch, E, Villiger, PM, Welton, NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ, 341, 2010, c4675, 10.1136/bmj.c4675.
Hathcock, JN, Shao, A, Risk assessment for glucosamine and chondroitin sulfate. Regul Toxicol Pharmacol 47:1 (2007), 78–83, 10.1016/j.yrtph.2006.07.004.
Singh, JA, Noorbaloochi, S, MacDonald, R, Maxwell, LJ, Chondroitin for osteoarthritis. Cochrane Database Syst Rev, 1, 2015, CD005614, 10.1002/14651858.CD005614.pub2.
Pelletier, JP, Martel-Pelletier, J, Diacerein-containing products: same risk of diarrhoea?. Aging Clin Exp Res 30:4 (2018), 411–412, 10.1007/s40520-018-0911-3.
Olivier, P, Montastruc, JL, Reseau francais des centres regionaux de p. [Post-marketing safety profile of avocado-soybean unsaponifiables]. Presse Med 39:10 (2010), e211–e216, 10.1016/j.lpm.2010.01.013.
Garvey, WT, Olefsky, JM, Matthaei, S, Marshall, S, Glucose and insulin co-regulate the glucose transport system in primary cultured adipocytes. A new mechanism of insulin resistance. J Biol Chem. 262:1 (1987), 189–197.
Marshall, S, Bacote, V, Traxinger, RR, Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 266:8 (1991), 4706–4712.
Baron, AD, Zhu, JS, Zhu, JH, Weldon, H, Maianu, L, Garvey, WT, Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Investig 96:6 (1995), 2792–2801, 10.1172/JCI118349.
Pouwels, MJ, Jacobs, JR, Span, PN, Lutterman, JA, Smits, P, Tack, CJ, Short-term glucosamine infusion does not affect insulin sensitivity in humans. J Clin Endocrinol Metab 86:5 (2001), 2099–2103, 10.1210/jcem.86.5.7470.
Monauni, T, Zenti, MG, Cretti, A, Daniels, MC, Targher, G, Caruso, B, et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes 49:6 (2000), 926–935.
Muniyappa, R, Karne, RJ, Hall, G, Crandon, SK, Bronstein, JA, Ver, MR, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes 55:11 (2006), 3142–3150, 10.2337/db06-0714.
Clegg, DO, Reda, DJ, Harris, CL, Klein, MA, O'Dell, JR, Hooper, MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354:8 (2006), 795–808, 10.1056/NEJMoa052771.
Palma Dos Reis, R, Giacovelli, G, Girolami, F, Andre, R, Bonazzi, A, Rovati, LC, Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials. Open Rheumatol J 5 (2011), 69–77, 10.2174/1874312901105010069.
Herrero-Beaumont, G, Ivorra, JA, Del Carmen Trabado, M, Blanco, FJ, Benito, P, Martin-Mola, E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 56:2 (2007), 555–567, 10.1002/art.22371.
Dostrovsky, NR, Towheed, TE, Hudson, RW, Anastassiades, TP, The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. Osteoarthr Cartil 19:4 (2011), 375–380, 10.1016/j.joca.2011.01.007.
Simon, RR, Marks, V, Leeds, AR, Anderson, JW, A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev 27:1 (2011), 14–27, 10.1002/dmrr.1150.
Gommans, YMM, Runhaar, J, Jacobs, ML, Bierma-Zeinstra, SMA, The effect of prolonged glucosamine usage on HbA1c Levels and new-onset diabetes mellitus in overweight and obese middle-aged women. Am J Med 130:6 (2017), 731-7 e6–737, 10.1016/j.amjmed.2016.11.038 e6.
Runhaar, J, Deroisy, R, van Middelkoop, M, Barretta, F, Barbetta, B, Oei, EH, et al. The role of diet & exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: further results from the Prevention of Knee Osteoarthritis in Overweight Females (PROOF) study. Semin Arthritis Rheum 45:Suppl 4S (2016), S42–SS8.
Mylan. DONA (crystalline glucosamine sulfate1500 mg powder): summary of product characteristics 2018 2018.
Habib, GS, Systemic effects of intra-articular corticosteroids. Clin Rheumatol 28:7 (2009), 749–756, 10.1007/s10067-009-1135-x.
Choudhry, MN, Malik, RA, Charalambous, CP, Blood glucose levels following intra-articular steroid injections in patients with diabetes: a systematic review. JBJS Rev, 4(3), 2016, 10.2106/JBJS.RVW.O.00029.
Cooper, C, Bardin, T, Brandi, M-L, Cacoub, P, Caminis, J, Civitelli, R, et al. Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clin Exp Res 28:1 (2016), 1–16, 10.1007/s40520-015-0522-1.
Bannuru, RR, Vaysbrot, EE, Sullivan, MC, McAlindon, TE, Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 43:5 (2014), 593–599, 10.1016/j.semarthrit.2013.10.002.
Bannuru, RR, Natov, NS, Obadan, IE, Price, LL, Schmid, CH, McAlindon, TE, Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 61:12 (2009), 1704–1711, 10.1002/art.24925.
Bannuru, RR, Osani, M, Vaysbrot, EE, McAlindon, TE, Comparative safety profile of hyaluronic acid products for knee osteoarthritis: a systematic review and network meta-analysis. Osteoarthr Cartil 24:12 (2016), 2022–2041, 10.1016/j.joca.2016.07.010.
Bannuru, RR, Schmid, CH, Kent, DM, Vaysbrot, EE, Wong, JB, McAlindon, TE, Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 162:1 (2015), 46–54, 10.7326/M14-1231.
Maheu, E, Bannuru, RR, Herrero-Beaumont, G, Allali, F, Bard, H, Migliore, A, Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: results of an extensive critical literature review. Semin Arthritis Rheum, 2018, 10.1016/j.semarthrit.2018.06.002.
Cooper, C, Rannou, F, Richette, P, Bruyere, O, Al-Daghri, N, Altman, RD, et al. Use of intraarticular hyaluronic acid in the management of knee osteoarthritis in clinical practice. Arthritis Care Res 69:9 (2017), 1287–1296, 10.1002/acr.23204.
Maheu, E, Rannou, F, Reginster, JY, Efficacy and safety of hyaluronic acid in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 45:4 Suppl (2016), S28–S33, 10.1016/j.semarthrit.2015.11.008.
Altman, R, Lim, S, Steen, RG, Dasa, V, Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. health claims database. PLoS One, 10(12), 2015, e0145776, 10.1371/journal.pone.0145776.
Chen, CP, Hung, W, Lin, SH, Effectiveness of hyaluronic acid for treating diabetic foot: a systematic review and meta-analysis. Dermatol Ther 27:6 (2014), 331–336, 10.1111/dth.12153.
Wluka, AE, Lombard, CB, Cicuttini, FM, Tackling obesity in knee osteoarthritis. Nat Rev Rheumatol 9:4 (2013), 225–235, 10.1038/nrrheum.2012.224.
Springer, BD, Carter, JT, McLawhorn, AS, Scharf, K, Roslin, M, Kallies, KJ, et al. Obesity and the role of bariatric surgery in the surgical management of osteoarthritis of the hip and knee: a review of the literature. Surg Obes Relat Dis 13:1 (2017), 111–118, 10.1016/j.soard.2016.09.011.
Rubino, F, Nathan, DM, Eckel, RH, Schauer, PR, Alberti, KG, Zimmet, PZ, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39:6 (2016), 861–877, 10.2337/dc16-0236.
Pareek, M, Schauer, PR, Kaplan, LM, Leiter, LA, Rubino, F, Bhatt, DL, Metabolic surgery: weight loss, diabetes, and beyond. J Am Coll Cardiol 71:6 (2018), 670–687, 10.1016/j.jacc.2017.12.014.
Lindegaard, KK, Jorgensen, NB, Just, R, Heegaard, PM, Madsbad, S, Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetes. Diabetol Metab Syndr, 7, 2015, 12, 10.1186/s13098-015-0012-9.
Hafida, S, Mirshahi, T, Nikolajczyk, BS, The impact of bariatric surgery on inflammation: quenching the fire of obesity?. Curr Opin Endocrinol Diabetes Obes 23:5 (2016), 373–378, 10.1097/MED.0000000000000277.
Yadav, R, Hama, S, Liu, Y, Siahmansur, T, Schofield, J, Syed, AA, et al. Effect of Roux-en-Y bariatric surgery on lipoproteins, insulin resistance, and systemic and vascular inflammation in obesity and diabetes. Front Immunol, 8, 2017, 1512, 10.3389/fimmu.2017.01512.
Gallo, G, Candilio, G, De Luca, E, Iannicelli, A, Sciaudone, G, Pellino, G, et al. Bariatric surgery and rheumatic diseases: a literature review. Rev Recent Clin Trials 13:3 (2018), 176–183, 10.2174/1574887113666180314095445.
Groen, VA, van de Graaf, VA, Scholtes, VA, Sprague, S, van Wagensveld, BA, Poolman, RW, Effects of bariatric surgery for knee complaints in (morbidly) obese adult patients: a systematic review. Obes Rev 16:2 (2015), 161–170, 10.1111/obr.12236.
King, WC, Chen, JY, Belle, SH, Courcoulas, AP, Dakin, GF, Elder, KA, et al. Change in pain and physical function following bariatric surgery for severe obesity. JAMA 315:13 (2016), 1362–1371, 10.1001/jama.2016.3010.
Smith, TO, Aboelmagd, T, Hing, CB, MacGregor, A, Does bariatric surgery prior to total hip or knee arthroplasty reduce post-operative complications and improve clinical outcomes for obese patients? Systematic review and meta-analysis. Bone Joint J 98-B:9 (2016), 1160–1166, 10.1302/0301-620X.98B9.38024.
Nearing, EE 2nd, Santos, TM, Topolski, MS, Borgert, AJ, Kallies, KJ, Kothari, SN, Benefits of bariatric surgery before elective total joint arthroplasty: is there a role for weight loss optimization?. Surg Obes Relat Dis 13:3 (2017), 457–462, 10.1016/j.soard.2016.11.005.
Hooper, JM, Deshmukh, AJ, Schwarzkopf, R, The role of bariatric surgery in the obese total joint arthroplasty patient. Orthop Clin N Am 49:3 (2018), 297–306, 10.1016/j.ocl.2018.02.003.